Ulthera

Ultrasound for Neck Laxity

Ultrasound for Neck Laxity

In a study published in the Journal of Drugs in Dermatology (May 2016), Leslie Baumann, MD, and Brian Zelickson, MD, investigated whether application of microfocused ultrasound with high-resolution ultrasound visualization (MFU-V) at two focal depths would produce clinical results superior to treatment at a single focal depth. They used the Ulthera device, which administers MFU-V to produce noninvasive lifting and tightening of lax skin on the face and neck.

Cellulite Solution

Rollout of the FDA-approved Cellfina System provides a minimally invasive, long-lasting cellulite treatment option with high patient satisfaction levels.
Cellulite Solution

“We finally have a solution for many patients who come in complaining about cellulite,” says Daniel C. Mills, MD, director of the Aesthetic Plastic Surgical Institute in Laguna Beach, California, and one of four physicians chosen by Ulthera to work on clinical applications for its latest device, Cellfina.

Cellfina System Approved by FDA

Cellfina System Approved by FDA

The U.S. Food and Drug Administration (FDA) has cleared the Cellfina System (Ulthera) for long-term improvement (up to two years) in the appearance of cellulite on the buttocks and thighs. The Cellfina System combines highly advanced, proprietary technology with subcision to treat the primary structural cause of cellulite.

Ultherapy Approved for Décolleté Rejuvenation

Ultherapy Approved for Décolleté Rejuvenation

The ultrasound-based Ulthera System has received FDA clearance for the noninvasive treatment of lines and wrinkles on the chest or décolleté. The Ultherapy Décolletage Treatment takes about 30 minutes to perform with no downtime, and stimulates the natural formation of collagen and elastin in the skin’s foundation to gradually smooth chest wrinkles. Treatment results are visible after about three months.

Merz To Acquire Ulthera

MERZ TO ACQUIRE ULTHERA

Merz and Ulthera have entered into a definitive merger agreement, pursuant to which Merz will acquire global medical device company Ulthera, which developed the ultrasound-based Ultherapy technology for noninvasive skin tightening and lifting. Valued at up to $600 million in upfront cash and milestone payments, the acquisition is the largest in Merz’s history.

Ultrasound May Reduce Sebum Production in Acne Patients

Ulthera for acne reduction

Girish “Gilly” Munavalli, MD, presented the results of a study on the use of focused ultrasound (MFU-V, Ultherapy, www.ulthera.com) for the treatment of moderate to severe acne as a poster at the 2013 American Academy of Dermatology conference in Miami. The study followed 10 subjects with moderate to severe acne, defined as at least 20 lesions each of inflammatory papulopustular and comedonal acne. Each subject received three treatments spaced 14 days apart. Energy was delivered at 1.5mm/10MHz and 1.0mm/10MHz. Dr.